Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.12.016Source: DataRank Database

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia is a research paper published in Clinical Lymphoma Myeloma & Leukemia (2023). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 5.75)OA: greenTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Elias Jabbour ORCID,Trevor Jamison ORCID,Shilpa Paul ORCID,Branko Cuglievan ORCID,David McCall ORCID

Live enrichment

PubMed:38212207 PMC:PMC11804792 OpenAlex:https://openalex.org/W4390431304

National Cancer Institute

Grant: P30 CA016672

NCI NIH HHS

Grant: P50 CA100632

National Institutes of Health

University of Texas MD Anderson Cancer Center

FWCI

5.75

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11804792/pdf/nihms-2052943.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2152265023022164?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2152265023022164?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11804792

Fields of Study

Acute Lymphoblastic Leukemia researchCAR-T cell therapy researchChronic Myeloid Leukemia Treatments

MeSH Terms

Inotuzumab OzogamicinAgedCardiovascular DiseasesHumansPhiladelphia ChromosomeRetrospective StudiesPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntibodies, BispecificPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

BlinatumomabMedicineLymphoblastic LeukemiaPhiladelphia chromosomeCD22OncologyInternal medicineLeukemiaB cellImmunologyGeneticsChromosomal translocationGeneAntibodyBispecific antibodyCD19ChemoimmunotherapyAntibody-drug Conjugate

Sustainable Development Goals

SDG 0: Good health and well-being

Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia

FAIR Checklist

Authors (16)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)